Aignostics Unveils Atlas 2: A Revolutionary Pathology Foundation Model

In a groundbreaking announcement, Aignostics has introduced Atlas 2, a highly advanced version of its pathology foundation model, which has been meticulously developed in collaboration with renowned institutions such as the Mayo Clinic, LMU Munich, and Charité – Universitätsmedizin Berlin. This updated version is touted as a game-changer in the pathology field and sets new industry standards by achieving top performance in 80 public benchmarks, leveraging the largest training dataset consisting of over 5 million slide images, and featuring an architecture that boasts around 2 billion parameters.

The significance of Atlas 2 goes beyond sheer size. It exemplifies exceptional robustness—an essential characteristic for clinical applications—and is accompanied by high-quality regulatory documentation to facilitate its integration into medical devices. The development team has also created streamlined versions of the model that maintain elite performance, opening opportunities for widespread application across various healthcare domains.

"Atlas 2 embodies our commitment to delivering not only the most advanced AI technology but also the most clinically applicable solutions," explained Maximilian Alber, Aignostics' co-founder and technical lead. He emphasized that rigorous evaluation through public benchmarks, paired with maintaining clinical-level regulatory documentation, ensures seamless integration of these advancements into clinical workflows.

Aignostics plans to incorporate Atlas 2 into its entire product line, including the Atlas HE-TME application, designed to profile tumor microenvironments in HE slides. Furthermore, Atlas 2 will be available for licensing, expanding its reach into research and clinical settings.

Jim Rogers, the digital pathology division manager at Mayo Clinic, commented on the partnership, stating, “Atlas 2 is a testament to the ongoing strength of our collaboration with Aignostics. These results reflect real progress in developing AI tools that can transform pathology for patient benefit.”

About Aignostics

Aignostics is an innovative AI company dedicated to transforming complex pathology data into insightful conclusions. By combining proprietary access to multimodal clinical data with industry-leading technology and rigorous scientific methods, Aignostics is at the forefront of developing cutting-edge products and services for the next generation of precision medicine. The company supports drug discovery, translational research, clinical trials, and companion diagnostics (CDx) development through collaborations with its biopharma partners. Notably, Aignostics' latest offering, Atlas HE-TME, is a self-service application that provides comprehensive profiling of tumor microenvironments in HE images with single-cell resolution, granting researchers unprecedented precision and scalability.

Founded in 2018, Aignostics emerged as a spin-off from Charité Berlin, recognized as one of the largest and most prestigious university hospitals in the world. With backing from leading investors, Aignostics maintains offices in Berlin and New York.